Clopidogrel vs Aspirin According to Diabetes Mellitus
JACC: Cardiovascular Interventions · 2026
DOI: 10.1016/j.jcin.2026.05.013 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2026. Verfasst von Sang Yoon Lee und 37 weiteren Autor:innen. Beteiligte Einrichtung: Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Clopidogrel, Platelet Aggregation Inhibitors, Aspirin, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
BACKGROUND: Recent trials support the superior efficacy of clopidogrel compared to aspirin monotherapy after completion of dual antiplatelet therapy (DAPT) in patients who have undergone percutaneous coronary intervention (PCI). However, limited evidence is available in patients with diabetes mellitus (DM). OBJECTIVES: This study sought to evaluate the comparative efficacy and safety of clopidogrel vs aspirin monotherapy according to the presence of DM. METHODS: This was a prespecified analysis of the SMART-CHOICE 3 trial, which was a multicenter, open-label, randomized controlled trial comparing clopidogrel vs aspirin monotherapy in patients with complex coronary lesions or high-risk clinical characteristics. From August 2020 to July 2023, a total of 5,506 patients who underwent PCI and standard DAPT duration and had complex coronary lesions, DM, or previous myocardial infarction, were randomized to clopidogrel or aspirin monotherapy groups. The primary endpoint was major adverse cardiac and cerebrovascular events (MACCE), which was defined as a composite of death from any cause, myocardial infarction, or stroke. RESULTS: Of 5,506 patients, 2,089 had DM (1,039 in the clopidogrel group and 1,050 in the aspirin group). At a median follow-up of 2.3 years (IQR: 1.6-3.0 years), DM patients had a higher risk of MACCE compared to non-DM patients (6.8% vs 4.7%; HR: 1.44, 95% CI: 1.10-1.87; P = 0.008). Clopidogrel showed a significantly lower risk of MACCE than aspirin in DM patients (4.5% vs 9.1%; HR: 0.57, 95% CI: 0.38-0.86; P = 0.008). There was no significant interaction between DM and antiplatelet monotherapy regarding MACCE (P for interaction = 0.124). The risk of bleeding was comparable between the 2 groups in DM patients (2.9% vs 2.9%; HR: 1.06, 95% CI: 0.57-1.95; P = 0.855). CONCLUSIONS: Among DM patients who completed the standard duration of DAPT after PCI, clopidogrel monotherapy was associated with a lower risk of a composite of death from any cause, myocardial infarction, and stroke compared with aspirin monotherapy, without increased rates of bleeding. There was no significant interaction between DM and antiplatelet monotherapy with respect to MACCE. (SMART-CHOICE 3 [SMart Angioplasty Research Team: CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3]; NCT04418479).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Wonkwang University Hospital, Iksan, Korea.
- Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address: joomyung.lee@samsung.com.
- Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.
- Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
- Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea.
Zitieren
APA
Lee, S. Y., Joo, D., Lee, J. M., Park, Y. H., Lee, J. Y., Jeong, J. O., Kim, C. J., Lee, H. C., Chang, K., Park, M. W., Bae, J. W., Doh, J. H., Cho, B. R., Kim, H. Y., Kim, W., Kim, U., Rha, S. W., Hong, Y. J., Lee, H. J., …, & SMART-CHOICE 3 Investigators (2026). Clopidogrel vs Aspirin According to Diabetes Mellitus. JACC: Cardiovascular Interventions. https://doi.org/10.1016/j.jcin.2026.05.013
Vancouver
Lee SY, Joo D, Lee JM, Park YH, Lee JY, Jeong JO, et al. Clopidogrel vs Aspirin According to Diabetes Mellitus. JACC: Cardiovascular Interventions. 2026. doi:10.1016/j.jcin.2026.05.013
BibTeX
@article{Lee2026,
author = {Lee, Sang Yoon and Joo, Donghyeon and Lee, Joo Myung and Park, Yong Hwan and Lee, Jong-Young and Jeong, Jin-Ok and Kim, Chan Joon and Lee, Han Cheol and Chang, Kiyuk and Park, Mahn-Won and Bae, Jang-Whan and Doh, Joon-Hyung and Cho, Byung Ryul and Kim, Hee-Yeol and Kim, Weon and Kim, Ung and Rha, Seung-Woon and Hong, Young Joon and Lee, Hyun-Jong and Ahn, Sung Gyun and Kim, Doo-Il and Cho, Jang Hyun and Her, Sung Ho and Jeon, Doo Soo and Han, Seung Hwan and Lee, Jin-Bae and Lee, Cheol Whan and Kang, Danbee and Choi, Ki Hong and Park, Taek Kyu and Yang, Jeong Hoon and Lee, Soo-Youn and Choi, Seung-Hyuk and Gwon, Hyeon-Cheol and Song, Young Bin and Hahn, Joo-Yong and Yun, Kyeong Ho and SMART-CHOICE 3 Investigators, SMART-CHOICE 3 Investigators},
title = {Clopidogrel vs Aspirin According to Diabetes Mellitus},
journal = {JACC: Cardiovascular Interventions},
year = {2026},
doi = {10.1016/j.jcin.2026.05.013}
}
EUVIMED